Printer Friendly

Coury succeeds Puskar as Mylan CEO. (RX/News).

PITTSBURGH -- Robert Coury has been named chief executive officer of Mylan Laboratories Inc. He will replace Milan Puskar, who co-founded the pharmaceutical company in 1961.

"We have long felt that it was a priority for Mylan to identify the next generation of leaders for our company," says Puskar, who will continue as chairman. "We have been fortunate to find that talent."

Mylan makes over 100 branded and generic drugs and is expected to generate sales this year of more than $1.1 billion.

Coury joined the supplier's board in February and became vice chairman the following month. The principal of a corporate strategy firm he formed in 1989, Coury has been a consultant Mylan since 1995.

Louis DeBone has been designated president and chief operating officer, succeeding A.B. Todd, who had been acting president and chief operating officer. Todd, who will retire effective September 1, will retain his seats on the board and Mylan's executive committee.

DeBone has been affiliated with the company since 1976, initially with Mylan Pharmaceuticals Inc., the generics division.

Puskar is credited with having established one of the best manufacturing operations among drug makers and in helping to convince regulators that generic drugs are equivalent to branded medicines and should thus be allowed on the market. In March 2001, he and other Mylan executives helped defeat Bristol-Myers Squibb Co. in a legal contest over the latter's monopoly on BuSpar.

Mylan was given six months exclusivity as the only generic maker of certain doses of the anxiety drug.

COPYRIGHT 2002 Racher Press, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2002 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Robert Coury; Milan Puskar; Mylan Laboratories Inc.
Comment:Coury succeeds Puskar as Mylan CEO. (RX/News).(Robert Coury; Milan Puskar; Mylan Laboratories Inc.)
Publication:Chain Drug Review
Article Type:Brief Article
Geographic Code:1USA
Date:Aug 5, 2002
Words:252
Previous Article:Par, Nortec expand alliance. (RX/News).
Next Article:Bisanz sets ambitious goals at CACDS. (RX/News).
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters